Any disappointment from ISIS Pharmaceuticals (ISIS +0.40%) recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month.
Wall Street is incredibly excited as well, with Piper Jaffray boldly declaring Isis as having the best pipeline in biotech and an obvious takeover target.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass talk Isis' large drug pipeline, its clincal trial success, and why ISIS could be attracting buyout attention.
